Annalisa Morgan, MD
Assistant Professor of NeurologyAbout
Research
Publications
2024
Characteristics and Clinical Significance of Initial MRI in Anti-NMDA Receptor Encephalitis (P5-14.019)
Lambe J, Abrah A, Morgan A, Thompson N, Lee J, Kunchok A. Characteristics and Clinical Significance of Initial MRI in Anti-NMDA Receptor Encephalitis (P5-14.019). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205442.Peer-Reviewed Original ResearchParaneoplastic Immune Mediated
Morgan A, Kunchok A. Paraneoplastic Immune Mediated. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.19-10.20.ChaptersOther Neuroimmunologic Syndromes
Morgan A, Abbatemarco J. Other Neuroimmunologic Syndromes. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.17.ChaptersStiff-Man Syndrome
Morgan A, Abbatemarco J. Stiff-Man Syndrome. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.18.ChaptersIatrogenic Epileptogenicity Caused by CNS Drugs: A Short Case Series and Narrative Review
Morgan A, Punia V. Iatrogenic Epileptogenicity Caused by CNS Drugs: A Short Case Series and Narrative Review. The Neurohospitalist 2024, 14: 291-295. PMID: 38895019, PMCID: PMC11181966, DOI: 10.1177/19418744241239382.Peer-Reviewed Original ResearchCentral nervous systemAnti-seizure medicationsInterictal epileptiform dischargesShort case seriesCentral nervous system drugsNon-epileptic movement disordersCase seriesEpileptiform dischargesCNS medicationsEpileptogenicitySeizure disorderMultiple medicationsClinical casesNervous systemCNS drugsMedicationMovement disordersSeizuresNarrative reviewDrugDisordersElectroencephalogramLongitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis
Morgan A, Li Y, Thompson NR, Milinovich A, Abbatemarco JR, Cohen JA, Ontaneda D, Punia V, Rae-Grant A, Galioto R, Kunchok A. Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis. Neurology. 2024 Feb 27;102(4):e208019. doi: 10.1212/WNL.0000000000208019. Epub 2024 Jan 24. PMID: 38266213.Peer-Reviewed Original ResearchManagement Approaches in Radiographically Isolated Syndrome
Morgan A, Longbrake E. Management approaches in radiographically isolated syndrome. Practical Neurology (US). 2024;23(1):39-42.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLongitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis
Morgan A, Li Y, Thompson N, Milinovich A, Abbatemarco J, Cohen J, Ontaneda D, Punia V, Rae-Grant A, Galioto R, Kunchok A. Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis. Neurology 2024, 102: e208019. PMID: 38266213, DOI: 10.1212/wnl.0000000000208019.Peer-Reviewed Original ResearchConceptsModified Rankin ScaleAnti-NMDA receptor encephalitisLong-term follow-upCognitive impairmentPremorbid functioningOutcome measuresFollow-upSymptom onsetReceptor encephalitisModerate-severe cognitive impairmentReturn to premorbid functionGlobal motor functionLongitudinal outcomesShort-term follow-upIntensive care unit admissionFirst-line immunosuppressantModified Rankin Scale scoreSecond-line therapyMultiple clinical factorsMultiple outcome measuresMood symptomsShort-term outcomesDepression measuresLogistic regression modelsLong-term functional impairment
2023
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.
Morgan A, Tallantyre E, Ontaneda D. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother 2023, 23: 433-444. PMID: 37129299, DOI: 10.1080/14737175.2023.2208347.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLongitudinal clinical outcomes, cognitive impairment, and mood symptoms in anti-NMDAR encephalitis (P5-5.006)
Morgan A, Li Y, Thompson N, Rae-Grant A, Abbatemarco J, Punia V, Hantus S, Galioto R, Kunchok A. Longitudinal clinical outcomes, cognitive impairment, and mood symptoms in anti-NMDAR encephalitis (P5-5.006). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202839.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Annalisa Morgan, MD, is a neurologist who specializes in inflammatory disorders of the central nervous system. She focuses on conditions such as multiple sclerosis, neuromyelitis optic spectrum disorder (a rare autoimmune disease that affects the optic nerves and spinal cord), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD, an inflammatory condition that damages the protective covering of nerves in the brain, spinal cord, and optic nerves), and autoimmune encephalitis (a condition in which the immune system mistakenly attacks the brain, causing inflammation).
An assistant professor of neurology at Yale School of Medicine, Dr. Morgan’s research is dedicated to clinical trials exploring new treatment therapies and strategies.
“We have come a long way in the last few decades in our care of patients with multiple sclerosis and other neuroimmunologic diseases,” she says, “but we still have more to learn, especially in how we can better optimize our long-term care.”
Dr. Morgan received her medical training from Rush Medical College, completed her neurology residency at the Cleveland Clinic, and pursued fellowship training in neuroimmunology at Yale School of Medicine.
Clinical Specialties
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Aaron Bower, MD - Annalisa Morgan, MD